The FDA revoked the emergency use authorization for AstraZeneca's Evusheld due to its expired shelf life and lack of patient administration approval for over a year.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
The current price of AZN1/N is 3,047.68 MXN — it hasn't changed in the past 24 hours. Watch ASTRAZENECA PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange ASTRAZENECA PLC stocks are traded under the ticker AZN1/N.
AZN1/N stock has risen by 0.00% compared to the previous week, the month change is a 0.00% rise, over the last year ASTRAZENECA PLC has showed a 38.75% increase.
We've gathered analysts' opinions on ASTRAZENECA PLC future price: according to them, AZN1/N price has a max estimate of 4,676.51 MXN and a min estimate of 2,716.62 MXN. Watch AZN1/N chart and read a more detailed ASTRAZENECA PLC stock forecast: see what analysts think of ASTRAZENECA PLC and suggest that you do with its stocks.
AZN1/N reached its all-time high on Dec 18, 2024 with the price of 3,047.68 MXN, and its all-time low was 2,196.58 MXN and was reached on Nov 16, 2023. View more price dynamics on AZN1/N chart. See other stocks reaching their highest and lowest prices.
AZN1/N stock is 0.00% volatile and has beta coefficient of 1.28. Track ASTRAZENECA PLC stock price on the chart and check out the list of the most volatile stocks — is ASTRAZENECA PLC there?
Today ASTRAZENECA PLC has the market capitalization of 4.09 T, it has decreased by −0.67% over the last week.
ASTRAZENECA PLC is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
AZN1/N earnings for the last quarter are 40.98 MXN per share, whereas the estimation was 40.25 MXN resulting in a 1.83% surprise. The estimated earnings for the next quarter are 42.90 MXN per share. See more details about ASTRAZENECA PLC earnings.
ASTRAZENECA PLC revenue for the last quarter amounts to 267.28 B MXN, despite the estimated figure of 257.64 B MXN. In the next quarter, revenue is expected to reach 285.46 B MXN.
AZN1/N net income for the last quarter is 28.96 B MXN, while the quarter before that showed 35.42 B MXN of net income which accounts for −18.23% change. Track more ASTRAZENECA PLC financial stats to get the full picture.
ASTRAZENECA PLC dividend yield was 2.15% in 2023, and payout ratio reached 73.66%. The year before the numbers were 2.13% and 138.71% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 24, 2024, the company has 89.90 K employees. See our rating of the largest employees — is ASTRAZENECA PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ASTRAZENECA PLC EBITDA is 328.29 B MXN, and current EBITDA margin is 31.31%. See more stats in ASTRAZENECA PLC financial statements.
Like other stocks, AZN1/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASTRAZENECA PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ASTRAZENECA PLC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ASTRAZENECA PLC stock shows the strong buy signal. See more of ASTRAZENECA PLC technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.